<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786734</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-PTV-705</org_study_id>
    <nct_id>NCT00786734</nct_id>
  </id_info>
  <brief_title>Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)</brief_title>
  <official_title>A Randomized, Open Label, Comparative Study to Evaluate Effect of Pitavastatin for Reduction of Myocardial Damage in Patient Are Scheduled Elective PCI for Stable Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without
      pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin
      levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation).
      After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedural ischemic myocardial injury remains the most frequent complication after coronary
      angioplasty. Recently it was reported that pretreatment with atorvastatin reduce the
      myocardial damage compared to placebo. Thus, we will evaluate the difference of pretreatment
      of pitavastatin compared to standard therapy on the reduction of myocardial damage in patient
      who is scheduled elective PCI for stable angina pectoris.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients whose CK-MB &gt; 2 times above UNL</measure>
    <time_frame>First evaulation time (before PCI)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who show any increase of CK-MB, troponin I, and myoglobin above UNL</measure>
    <time_frame>First evaluation time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean peak values of CK-MB, troponin I and myoglobin after intervention</measure>
    <time_frame>After PCI (&lt;24hrs)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of hs-CRP, wall motion score</measure>
    <time_frame>Second evaluation time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of all major adverse cardiac events</measure>
    <time_frame>Second evaluation time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Pitavastatin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI</description>
    <arm_group_label>Pitavastatin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>4mg daily for 28 days after PCI</description>
    <arm_group_label>Usual Care Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with LDL ≥ 100mg/dL

          -  Patients who are scheduled an elective PCI for stable angina

        Exclusion Criteria:

          -  Acute myocardial infarction (&lt;3 months)

          -  Unstable angina

          -  Previous treatment with statins (&lt;6 months)

          -  Increase in CK-MB above upper normal limit

          -  Increase in liver enzymes (AST/ALT) above 2 times of upper normal limit

          -  Increase in serum creatinine above 2 times of upper normal limit

          -  Left ventricular ejection fraction &lt;30%

          -  Previous treatment with glycoprotein Ⅱb/Ⅲa receptor inhibitor (&lt;4 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Bae Seung, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Catholic University of Korea Kangnam St. Mary's Hospital located</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Korea Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pitavastatin</keyword>
  <keyword>PCI</keyword>
  <keyword>stable angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

